Charles River ups microbial solutions offering

By Melissa Fassbender contact

- Last updated on GMT

(Image credit: Charles River Laboratories)
(Image credit: Charles River Laboratories)

Related tags: Charles river laboratories

Charles River has added to its microbial solutions offering with two new products that aim to reduce risk and increase the efficiency of drug testing.

Charles River Laboratories has launched two new products in its microbial solutions portfolio including an update to its Endosafe EndoScan-V software, which, when combined with the company’s Endosafe instruments and reagents, provides “a complete endotoxin detection system,” ​said Julie Sperry, senior director, microbial solutions product management and strategic marketing, Charles River.

The software was designed with flexible capabilities and performance options, such as instrument management, an accessories database, and electronic signature, according to the company.

Said Sperry, “The software encompasses all the pillars of data integrity compliance – a fully searchable audit trail, flexible user control and management, and reliable data generation and backup.”

“With the industry heavily focused on the compliance to regulatory requirements, EndoScan-V meets the highest standards of data integrity and provides users confidence in the quality of their endotoxin detection data and therefore the quality of their drug products,”​ she added.

The company also has introduced its ‘Celsis’ automated detection solution for sterility, which Sperry said delivers quality control results in six days – compared to the 14-day industry average.

This two-week ‘wait’ can introduce “unnecessary risk into the production process in the event of a contamination failure, additional inventory storage requirements, product hold times, and delays to market,”​ said Sperry.

“This time savings allows manufacturers to quickly confirm the presence or absence of microbial contamination, and ultimately, release critical therapies to patients faster and more safely,”​ she added, “since there are no changes to the established sample prep method compared to the traditional test, validation and training are straightforward.”

Related news

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more